Opinion
Video
Oral Systemics for the Treatment of Plaque Psoriasis
Author(s):
April W. Armstrong, MD, MPH, discusses emerging therapies in oral systemics for the treatment of plaque psoriasis and shares developments in TYK2 inhibition.
This is a video synopsis of a discussion involving April W. Armstrong, MD, MPH, Professor and Chief of Dermatology at UCLA, and Chair Emeritus of the Medical Board of the National Psoriasis Foundation. Dr. Armstrong specializes in psoriasis and atopic dermatitis.
Dr. Armstrong discusses recent advancements in oral medications for psoriasis and atopic dermatitis. Traditionally, there has been a trade-off between efficacy and safety with oral medications. However, in the last two years, a new class of medications called TYK2 (Tyrosine Kinase 2) inhibitors has emerged. These drugs specifically target TYK2, a molecule critical for IL-23 (interleukin 23) signal transmission, pivotal in psoriasis pathogenesis.
In 2022, the FDA approved deucravacitinib, an allosteric inhibitor of TYK2, making it more selective and with fewer spillover effects. Dr. Armstrong notes ongoing clinical trials for other TYK2 inhibitors, including TAC (tacrolimus), and another TYK2 inhibitor in later phase trials.
The focus in the field is shifting towards TYK2 inhibition, moving away from JAK1 (Janus kinase 1) inhibition, particularly for plaque psoriasis. Additionally, Dr. Armstrong mentions other oral medications being explored, including peptides targeting the IL-23 receptor and small molecules mimicking IL-17 (interleukin 17) biologics.
The discussion underscores the exciting research in the oral medication space for psoriasis and atopic dermatitis, with numerous options in the pipeline for patients.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
